From Self-sufficiency
Jump to: navigation, search
File:Apraclonidine structure.svg
Systematic (IUPAC) name
2,6-dichloro-N- (4,5-dihydro-1H-imidazol-2-yl) benzene-1,4-diamine
Clinical data
Routes of
Ophthalmic solution
Legal status
Legal status
  • ℞ (Prescription only)
Pharmacokinetic data
Protein binding 98.7%
Biological half-life 8 hours
CAS Number 66711-21-5
ATC code S01EA03 (WHO)
PubChem CID 2216
DrugBank APRD00012
ChemSpider 2130
Chemical data
Formula C9H10Cl2N4
Molar mass 245.108 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Apraclonidine (INN), also known as Iopidine, is a sympathomimetic used in glaucoma therapy. It is an α2-adrenergic agonist.

Apraclonidine is administered at a concentration of 1% for the prevention and treatment of postsurgical intraocular pressure elevation and 0.5% for short-term adjunctive therapy in patients on maximally tolerated medical therapy who require additional redirection of intraocular pressure. One drop is usually added one hour prior to laser eye surgery and another drop is given after the procedure is complete.

Clinical uses

Apraclonidine is indicated for the short-term adjunctive treatment of patients on maximally tolerated medical therapy who require additional IOP reduction. Patients on maximally tolerated medical therapy who are treated with apraclonidine to delay surgery should have frequent followup examinations and treatment should be discontinued if the intraocular pressure rises significantly.

External links


  • Chen P, Chen J, Lu D, Chen Y, Hsiao C (2006). "Comparing efficacies of 0.5% apraclonidine with 4% cocaine in the diagnosis of horner syndrome in pediatric patients". J Ocul Pharmacol Ther. 22 (3): 182–7. doi:10.1089/jop.2006.22.182. PMID 16808679. 
  • Aslanides l, Tsiklis N, Ozkilic E, Coskunseven E, Pallikaris l, Jankov M (2006). "The effect of topical apraclonidine on subconjunctival hemorrhage and flap adherence in LASIK patients". J Refract Surg. 22 (6): 585–8. PMID 16805122. 
  • Koc F, Kansu T, Kavuncu S, Firat E (2006). "Topical apraclonidine testing discloses pupillary sympathetic denervation in diabetic patients". J Neuroophthalmol. 26 (1): 25–9. doi:10.1097/01.wno.0000204648.79744.71. PMID 16518162. 
  • Garibaldi D, Hindman H, Grant M, Iliff N, Merbs S (2006). "Effect of 0.5% apraclonidine on ptosis in Horner syndrome". Ophthal Plast Reconstr Surg. 22 (1): 53–5. doi:10.1097/01.iop.0000196322.05586.6a. PMID 16418668. 
  • Onal S, Gozum N, Gucukoglu A (2005). "Effect of apraclonidine versus dorzolamide on intraocular pressure after phacoemulsification". Ophthalmic Surg Lasers Imaging. 36 (6): 457–62. PMID 16355950.